Excited to share our contribution to the development of a groundbreaking PET ligand for imaging of non-AD tauopathies!
Offspring Biosciences is thrilled to announce our contribution to the development of [18F]OXD-2314, a groundbreaking PET ligand for imaging tau aggregation in non-Alzheimer's disease (AD) tauopathies. This research, recently published in Nature Communication represents a significant step forward in the diagnosis and monitoring of these debilitating disorders.
The team behind this research, which included among others, scientists at Novandi Chemistry AB and Oxiant Discovery AB, in Södertälje, Sweden, successfully optimized a lead compound, [18F]OXD-2115, to create [18F]OXD-2314. This new radiotracer offers high affinity for tau protein aggregates, specifically targeting non-AD forms. This achievement holds immense potential for improved diagnosis and evaluation of treatment efficacy in various tauopathies.
At Offspring Biosciences, we are committed to supporting research that advances the understanding and treatment of neurodegenerative diseases. We are proud to have played a supporting role in this crucial development and look forward to the continued advancement of [18F]OXD-2314 towards clinical application.
Read the full article at Nature Communications here.
